WO2026053168 - AMORPHOUS FORMS OF A ROCK2 INHIBITOR AND FORMULATIONS THEREOF
National phase entry is expected:
Publication Number
WO/2026/053168
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058967
International Filing Date
05.09.2025
Title **
[English]
AMORPHOUS FORMS OF A ROCK2 INHIBITOR AND FORMULATIONS THEREOF
[French]
FORMES AMORPHES D'UN INHIBITEUR DE ROCK2 ET FORMULATIONS ASSOCIÉES
Applicants **
GRAVITON BIOSCIENCE BV
Inventors
WAKSAL, Samuel D.
WU, Rui
ZHU, Jiahao
Priority Data
63/691,603
06.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2512 | |
| EPO | Filing, Examination, Granting | 15971 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 3015 | |
| USA | Filing, Examination, Granting | 11540 |
Total:
35,656
Contact Us
Abstract[English]
The present disclosure relates to amorphous forms of (6-(4-((4-(1H-pyrazol-4- yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone (Compound A) and processes for preparing amorphous forms of Compound A. The present disclosure also provides pharmaceutical dosage forms comprising the amorphous forms of Compound A as an active pharmaceutical ingredient and methods of preparing the pharmaceutical dosage forms.[French]
La présente divulgation concerne des formes amorphes de (6-(4-((4-(1H-pyrazol-4-yl)phényl)amino)pyrimidin-2-yl)-1-méthyl-1H-indol-2-yl)(3,3-difluoroazétidin-1-yl)méthanone (composé A) et des procédés de préparation de formes amorphes du composé A. La présente divulgation concerne également des formes posologiques pharmaceutiques comprenant les formes amorphes du composé A en tant que principe actif pharmaceutique et des procédés de préparation des formes posologiques pharmaceutiques.